#funding-deals

#funding-deals

Launching a fund used to be a real test of endurance, with timelines often stretching across many months. The process demanded patience that many ambitious founders found difficult to sustain.

Dr. Michael Burry of The Big Short fame doesn't seem to be willing to back down as a bear in the epic tug-of-war with Palantir shareholders and the great CEO Alex Karp. Undoubtedly, Burry seemed to have been getting his way, with shares of Palantir plunging viciously into a bear market amid one of the worst software slumps in recent memory.

Goldman Sachs' Chief Equity Strategist Peter Oppenheimer has called the recent sell-off in U.S. tech stocks a rare 'buying opportunity,' suggesting that the current market conditions may favor investment in this sector.

In March 2026, US startups raised $19.06 billion across 630 deals, a significant decline of 64.4% year-over-year from March 2025's $53.5 billion, which was heavily influenced by OpenAI's $40 billion mega-round.

Antioch aims to close the sim-to-real gap, addressing the challenge of making virtual environments realistic enough for robots to operate reliably in the physical world.

Awards may be encouraging and occasionally useful for visibility, but they are weak indicators of validation and poor predictors of long-term success. In the longevity and healthspan industry, where timelines are long and claims are easy to overstate, venture capital ultimately follows alignment and evidence, not applause received at glitzy industry events.

Helical's thesis is that bio foundation models, AI systems trained on vast genomic, transcriptomic, and proteomic datasets, have already crossed a quality threshold that makes computational hypothesis-testing meaningful in pharma research.